• 페이스북 공유하기
  • 트위터 공유하기

Introduction of Converging technology

  • Written on the basis of the report of NBIC Advancement Project

BT Convergence

Human/humanized antibody production

What is human/humanized antibody production technology?

  • It refers to the technology which manufactures human/humanized antibodies(biosimilars) with improved effect for treatment of serious intractable diseases such as cancer, immune disorder and infectious diseases.

Domestic and Foreign Research Trends

  • Europe has led the increasing development of biosimilars and USA is in its process of reinforcing biosimilar-related M&A and strategic alliances.
  • Korea also has a set of biotechnology companies such as LG Life Sciences, Hanhwa Chemical Corporation, Celltrion and IsuAbxisin the biosimilar industry.

Expected effect

  • The near future will witness enhanced global competitiveness of the medical/pharmaceutical field by developing biosimilars and new antibody drugs that can substitute several blockbuster biopharmaceuticals of which the patents expire in a few years

Core product and service

Core product and service
Core product/service Description Examples
Manufacture and massive production of human/
humanized antibodies
  • Biobetter products with doubled remedial effect than previous blockbuster antibody drugs (Production of antibody-drug conjugates, fragment antibodies or chimeric antibodies)
  • Cell lines which mass produce human/humanized antibodies
Aranesp, a biosimilar product ofEpoetin

Improvement and efficacy verification of human/
humanized antibodies
  • Their own verification technology that proves the efficacy of their antibodies similar to the previously released ones
  • Glyco chain engineering technology which improves the efficacy of antibody, and new scaffold application technology
Examples of human/humanized antibodies

Antibody improvement

What is antibody improvement technology?

  • It refers to the technology which produces new generation antibody drugs: for example, fragment antibodies, antibody analogues, antibody-drug zygotes and improved Glyco chain of antibodies

Domestic and Foreign Research Trends

  • Prolia of Amgen, Bapineuzumab of J&J and Pfiezer, and ndBenlystark of GSK are receiving great attention as new blockbuster antibodies
  • Biotrion, LG Life Science, Hanhwa Chemical Corporation and Celltrion are now conducting researches and clinical trials.

Expected effect

  • The near future will witness enhanced global competitiveness of the medical/pharmaceutical field by developing biosimilars and new antibody drugs that can substitute several blockbuster biopharmaceuticals of which the patents expire in a few years

Core product and service

Core product and service
Core product/service Description Examples
Manufacturing and massive production technology of fragment antibodies
  • The goal is to improve each fragment antibody depending on the domain features
  • The main targets for each domain: Fv is for affinity and specificity, Fc is for glycosylation or ADCC effect, and Fab is for the makeup for the weakness of fragment antibodies.
Various kinds of fragment antibodies

Antibody analog production and antibody Glyco chain improvement technology
  • Antibody analog production and antibody Glyco chain improvement technology
  • The technology of manufacturing antibodies conjugated with drugs or apoptosis-inducing proteins
  • The Glyco chain engineering technology for the improvement of antibody safety and cytopermeability
Antibody-drug conjugates of Roche (T-DM1)

Production/Cultivation of high expressing cell lines

What is the technology of producing and culturing high expressing cell lines?

  • It refers to the technology that produces therapeutic protein drugs of high quality: it involves technology of manufacturing and selecting high expressing cell lines(production host cells) and of producing high quality proteins by cultivating highly concentrated cell lines for a long time in a cultivator.
>

Domestic and Foreign Research Trends

  • The focus of the pharmaceutical market is now shifting to protein drugs from chemical drugs and biosimilar products of the therapeutic protein drugs are increasingly developed of which the patents will expire starting in 2013.
  • Some researches are being performed at the level of factor technology in Korea but converging technologies in this area is scarce.

Expected effect

  • It can make massive production possible within a short period of time and shorten the time to develop biopharmaceuticals, thereby reducing the unit cost of production and providing many patients with the benefit of high-quality bio medicinal products

Core product and service

Core product and service
Core product/service Description Examples
High-performance expressing vector system
  • Search for strong promoters and insulators which enhance the rate of gene expression
  • Search for terminators which effectively terminate gene expression
  • Search for DNA fragments which minimize the expression effect from a gene locus
  • STAR-Technology of Crucell
  • MAR Technology of Selexis
  • UCOE Technology of ML Laboratories
High-secretion host cell line system
  • Search for protein secretion control factors
  • The productivity decreases if the secretion rate is low even though the gene expression rate is high
  • Researches on chaperone regarding protein mobilization are being actively conducted
  • PER.C6 Technology of Crucell
Development of high-producing media technology
  • Search for dietary factors which affect the growth and productivity of cells
  • Evaluation of the influencing power depending on the optimization of the combination of medium components and production methods
  • Media products of HyClone
  • Media research service of Invitrogen, BD and others
Quality control and management of productive protein
  • Search for the causes of quality degradation resulting from high concentration production of protein
  • Development of probe which monitors and controls protein quality
 

Production of substitute substances for food additives

What is food additive substitute production technology?

  • Development and its functionality/safety of the substitutes for the existing natural and chemical food additives based on material conversion technology Environment-friendly food additive substitute technology for verification

Domestic and Foreign Research Trends

  • NIH of USA is leading researches on the safety of food additives, and Japan is actively conducting researches on the carcinogenicity of food additives
  • USA is implementing integrated management of materials for natural food additives with National Center of Biotechnology Information(NCBI), National Biological Information Infrastructure Initiative(NBII), and American Type Culture Collection(ATCC)

Expected effect

  • The development of useful materials from natural substances secures the diversity of resources, which was impossible due to the Convention on Biological Diversity(CBD)

Core product and service

Core product and service
Core product/service Description Examples
Alternative food additives for enhancing their storage and processing suitability
  • Substitution of the controversial food additive of sodium nitrite
  • Combination of fermentation technology and phytochemistry
  • Rapid growth in sales since its release from Moguchon Korea and CJ
Food additive substitutes for enhancing taste
  • Substitution of artificial dyes such as Food Red No.3 with natural food additive substances
  • Development of pilot products made of natural substances such as safflower dyestuff and grape skin extracts

Biomass component biosynthesis mechanism and control technology

What is biomass component biosynthesis mechanism and control technology?

  • It refers to the platform technology and renewable energy technology which analyze the components of biomasses to utilize them as the solution to the mineralization of energy sources and global warming

Domestic and Foreign Trends

  • Many companies in USA are now in progress of developing technology utilizing lignum biomass with the financial support of the government. Especially, the technology using enzyme fermentation is close to commercialization by such firms as DuPont, Verenium, Abengoa, Poet and Iogen
  • In Korea, venture businesses such as Bioland, Amicogen, and Genofocus are developing its application technology

Expected effect

  • In Korea, venture businesses such as Bioland, Amicogen, and Genofocus are developing its application technology
  • It may make substantial contribution to the achievement of the government’s goal of CO2 reduction by 2020 (20% reduction based on the BAU criterion)

Core product and service

Core product and service
Core product/service Description Examples
Biocatalysts for decomposing cellulose biomasses
  • Applicable to various kinds of biomass characteristics and has twice as much vitality as other products.
  • Useful in resisting inhibitors(Inhibitor) which hinder enzyme activity

[Novozyme] Cellic® CTec2 :
Cellulase Extraction

[Novozyme] Cellic® HTec2 :
Hemicellulase Extraction

Enzymes for producing biomass-based bio-ethanol
  • The enzyme cocktail commercially used in the cellulose ethanol industry
  • The enzyme capable of simultaneous use of C6 and C5 hydrocarbon
  • It may reduce conversion of Glucan and product inhibition, since ß-glucosidase is included

[Genecor] Accellerase®TRIO: Cellulase Extraction